Condition
PSA Level Greater Than or Equal to Two
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Unknown1
Withdrawn1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03442556Phase 2Terminated
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
NCT03709550Phase 1Withdrawn
Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer
NCT03501940Unknown
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
Showing all 3 trials